Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





CYANAMIDE								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 420-04-2; **Chemical Formula:** H2NC=N
Previously, OSHA had no limit for cyanamide. The ACGIH has a TLV-TWA of 2 mg/m3. The proposed PEL for cyanamide was 2 mg/m 3 as an 8-hour TWA; NIOSH (Ex. 8-47, Table N1) concurs that this limit is appropriate. An 8-hour PEL of 2 mg/m3 is established in the final rule. Undiluted cyanamide is a deliquescent, crystalline solid.
The average oral LD(50) for cyanamide in rats is 125 (85 to 180) mg/kg, and cyanamide has been observed to be very irritating and caustic to the skin (American Cyanamide Company Product Information Bulletin, as cited in ACGIH 1986/Ex. 1-3, p. 152). The dermal LD(50) in rabbits is 590 mg/kg (Dangerous Properties of Industrial Materials, 7th ed., Sax and Lewis 1989, p. 891). Irritation occurred in the form of primary skin irritation and, following instillation into the eye, slight irritation of the conjunctival sac (American Cyanamide Company Product Information Bulletin, as cited in ACGIH 1986/Ex. 1-3, p. 152).
When cyanamide is ingested or inhaled by a person who has also consumed an alcoholic beverage, the person experiences vasodilation of the face and neck, tachycardia, tachypnea, nausea, vomiting, and hypotension. This syndrome is referred to as the Antabuse effect. Studies of cyanamide’s Antabuse-like effects indicate that the effect is about one-half that of an equivalent dose of tetraethylthiuram disulfide (Antabuse) and one-sixth that of tetramethyl thiuram disulfide (Hald, Jacobsen, and Larsen 1952/Ex. 1-905).
OSHA received comments on cyanamide from the American Cyanamid Company (Exs. 8-76, 3-961, and 94). Linda Dulak, Toxicology Program Manager for American Cyanamid, argued that the final rule should not promulgate limits for substances for which there are no analytical methods (Ex. 3-961, p. 13). According to Dr. Dulak:
Without an analytical limit, the employer cannot determine whether employee exposures are being maintained below those limits...(Ex. 3-961, p. 13).
OSHA notes, however, that Dr. Dulak later stated (Tr. XI, p. 75) that American Cyanamid measures the airborne cyanamide level in their plants by sampling for calcium cyanamide. However, Dr. Dulak was unsure whether this method is applicable to hydrogen cyanamide. OSHA notes that a method for the sampling and analysis of cyanamide has been submitted to the docket.
According to Dr. Dulak (Ex. 3-961), OSHA also has not evaluated the technological and economic feasibility of the 2 mg/m3 limit for cyanamide. However, OSHA notes that American Cyanamid’s representatives testified at the hearing (Tr. XI, p. 76) that, although the company has no internal standard for cyanamide, it controls airborne cyanamide exposures by measuring and controlling airborne levels of calcium cyanamide. According to Dr. Dulak, her company has had “no problems” controlling cyanamide exposures (Tr. XI, p. 76).
Dr. Dulak’s third point is that there is no health basis for setting an inhalation limit for cyanamide (Ex. 3-961, p. 13). OSHA does not agree with this view and finds the evidence of cyanamide’s irritant properties sufficient to warrant the establishment of an 8-hour TWA limit. Sax and Lewis (Dangerous Properties of Industrial Materials, 7th ed., 1989, p. 981) note that this substance is a severe eye irritant, a moderately toxic substance by skin contact, and a poison by ingestion, inhalation, and intraperitoneal injection. The ACGIH (1986/Ex. 1-3, p. 152) set its limit, which is the same as the final rule’s PEL, on the basis of cyanamide’s relative potential to cause irritation when compared with other irritants (ACGIH 1986/Ex. 1-3, p. 152). Thus, OSHA finds the final rule’s PEL both appropriate and protective.
In the final rule, OSHA is establishing an 8-hour TWA limit of 2 mg/m3 TWA for cyanamide. The Agency concludes that this limit will protect against the significant risks of irritation and of the Antabuse syndrome in individuals who have ingested alcohol. The Agency has determined that this limit will substantially reduce these significant risks, which constitute material health impairments.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue